AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Axsome Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$155.81−1.33 (-0.85%)
Close on Oct 19, 2026
- Market cap
- $8.07B
- P/E (TTM)
- –
- Dividend yield
- –
Axsome Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Sales | $770.23M | $702.84M | $633.80M | $556.43M | $490.38M | $427.94M | $381.68M | $335.10M | $288.49M | $247.99M | $202.46M | $156.08M | 99.2% | +57.1% |
| License Fee | – | – | – | – | – | – | – | – | – | – | $65.74M | – | – | – |
| Royalty [Member] | – | – | – | – | – | – | – | $3.36M | $3.00M | $3.04M | $2.41M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Axsome Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.